Welcome to our dedicated page for Rapport Therapeutics news (Ticker: RAPP), a resource for investors and traders seeking the latest updates and insights on Rapport Therapeutics stock.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company that regularly issues news about its precision neuroscience programs for neurological and psychiatric disorders. The company’s updates often center on RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being evaluated in drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.
News for RAPP commonly includes clinical trial milestones, such as Phase 2a results in focal onset seizures, post hoc analyses presented at scientific meetings, and plans for registrational Phase 3 programs. Rapport has reported statistically significant reductions in long episodes and clinical seizures in its Phase 2a FOS trial, along with additional analyses on early onset of action, consistency of response, and improvements in seizure severity measures.
Investors and clinicians following Rapport can also expect announcements about regulatory interactions with the U.S. Food and Drug Administration, including end-of-Phase 2 meetings, clinical hold updates, and investigational new drug (IND)-enabling activities. The company provides updates on its long-acting injectable formulation of RAP-219, its α6β4 nicotinic acetylcholine receptor program for chronic pain and migraine, and other discovery and preclinical efforts in hearing and vestibular disorders.
RAPP news flow further covers financial and corporate developments, such as public offerings of common stock under an effective shelf registration statement, quarterly financial results, and participation in healthcare and investor conferences. For readers tracking Rapport Therapeutics, this news stream offers insight into the progress of its RAP technology platform, the evolution of its epilepsy portfolio, and the status of its broader pipeline in neurology and psychiatry.
Rapport Therapeutics, a clinical-stage biotech company, announced the pricing of its IPO at $17.00 per share for 8 million shares. Trading on the Nasdaq under the symbol 'RAPP' begins June 7, 2024, with the offering expected to close on June 10, 2024. Additionally, the company offers a 30-day option for underwriters to purchase up to 1.2 million more shares. Concurrently, Rapport will sell 1,058,824 shares in a private placement at the IPO price. Combined, these transactions aim to raise approximately $154 million before expenses, contingent on customary closing conditions. Joint book-running managers include Goldman Sachs, Jefferies, TD Cowen, and Stifel.